Elevated serum levels of GPX4, NDUFS4, PRDX5, and TXNRD2 as predictive biomarkers for castration resistance in prostate cancer patients: an exploratory study

By sjmartinez • February 4, 2025

Wang R, Wang S, Mi Y, Huang T, Wang J, Ni J, Wang J, Yin J, Li M, Ran X, Fan S, Sun Q, Tan SY, Phillip Koeffler H, Ding L, Chen YQ, Feng N. Elevated serum levels of GPX4, NDUFS4, PRDX5, and TXNRD2 as predictive biomarkers for castration resistance in prostate cancer patients: an exploratory study. Br J Cancer. 2025 Feb 3. doi: 10.1038/s41416-025-02947-0. Epub ahead of print. PMID: 39900986.

Tags: Cedars Sinai DoM, Hematology/Oncology, Publications

Blood Pressure Genetic Risk and Incident Hypertension at 2 to 7 Years Post Partum

Hemeryck J, De Moor N, Ezzat D, Khan RR, Vandergrift N, Levine LD, Rouse C, Theilen LH, Bairey Merz CN, Yee LM, Chung J, Bello[...]

Consensus Recommendations for Disease- and Treatment-Related Fatigue in Patients With Advanced Prostate Cancer: A Modified Delphi Panel

Freedland SJ, Aronson W, Asher A, Golant M, Lemke E, Morgans AK, Morris D, Sullivan C, Sutton J, Thomson CA, Twardowski P, Wefel JS, Winters-Stone[...]

A Multicomponent Approach to Screening for Dementia in Older Hospitalized Patients

Tan ZS, Qureshi N, Sicotte NL, Hirsch D, Escovedo C, Spivack E, Nasmyth MC, Gonzales M, Kremen SA, Nuckols TK, Mafi J, McFadden J, Roberts[...]